Results · Jul-Sep 2026 · filed 16 Oct 2026
Solara Active Pharma Sciences Q2 FY27 results
Sales grew 33% to ₹417 crore from ₹314 crore in Jul-Sep 2025.
Operating profit grew 121% to ₹76.8 crore, an operating margin of 18.4% (up 7.3 points from a year ago).
Net profit turned positive: ₹28.5 crore against a loss of ₹10.1 crore in Jul-Sep 2025.
Against Apr-Jun 2026: sales +9%, net profit +74%.
Jul-Sep 2026 vs a year ago
| ₹ crore | Jul-Sep 2026 | Jul-Sep 2025 | Change |
|---|---|---|---|
| Sales | 417.3 | 313.5 | +33% |
| Operating profit (EBITDA) | 76.8 | 34.7 | +121% |
| Operating margin | 18.4% | 11.1% | +7.3 pts |
| Net profit | 28.5 | -10.1 | turns positive |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 8 quarters
Filings that week
- 19 Oct 2026Announcement under Regulation 30 (LODR)-Newspaper Publication
- 17 Oct 2026Final Reminder-Cum-Forfeiture Notice To The Holders Of Partly Paid-Up Equity Shares Of The Company.
- 17 Oct 2026Announcement under Regulation 30 (LODR)-Newspaper Publication
- 16 Oct 2026Announcement under Regulation 30 (LODR)-Monitoring Agency Report
- 16 Oct 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- 16 Oct 2026Statement Of Deviation / Variation In Utilization Of Funds Raised For The Quarter Ended September 30, 2026.
- 16 Oct 2026Grant Of Employee Stock Options Under Solara Employee Stock Option Plan 2024.
- 16 Oct 2026Announcement under Regulation 30 (LODR)-Press Release / Media Release
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.